ScinoPharm Taiwan (台灣神隆), a leading active pharmaceutical ingredient (API) maker, yesterday announced that its profit rose 131 percent annually last quarter compared, driven by two new products.
ScinoPharm’s net profit was NT$406 million (US$13.5 million) in the April-to-June quarter, compared with NT$176 million in the same period last year, it said.
Last quarter’s figure was up 16 percent from NT$350 million the previous quarter, the firm said.
“Our new products — Qsymia and Viibryd — helped us increase our sales last quarter, while maintaining our gross margin and profit margin at 54 percent and 30 percent respectively,” ScinoPharm chief financial officer Patricia Chou (周珮芬) said at an investors’ conference yesterday.
Qsymia is a drug for chronic weight gain management, while Viibryd is an antidepressant, according to the company.
Revenue rose to NT$1.34 billion last quarter, up 13 percent from NT$1.19 billion a quarter ago and up 47 percent annually from NT$913 million, ScinoPharm said.
Daiwa Capital Markets analyst Christine Wang (王琦清) said in a statement yesterday that the pharmaceutical firm’s profit for last quater was 31 percent above analysts’ consensus estimate.
However, the company was still cautious about its outlook for the second half of the year.
“Our shipments this year were concentrated more in the first half, and it is unlikely that we will be able to repeat the strong performance of those first six months in the second half,” ScinoPharm president and chief executive Jo Shen (馬海怡) said.
Meanwhile, the company said it is planning to expand its sales in China and Japan this year, eyeing the growing API markets in both countries. The company expects its sales in Japan to increase to US$10 million this year from US$5.43 million last year.
That is because the company sees bigger growth potential there in view of the Japanese government’s decision to use more generic drugs and fewer new drugs developed by Japanese companies in a bid to save on national healthcare spending.
ScinoPharm also announced that it had formed a partnership with China-based Sundia MediTech Company Ltd (桑迪亞), a contract research organization, as part of the company’s efforts to offer a complete range of services from drug research to API manufacturing to its clients.
ScinoPharm shares declined 3.77 percent to NT$84.2 yesterday, underperforming the TAIEX, which was down 1.46 percent.
BYPASSING CHINA TARIFFS: In the first five months of this year, Foxconn sent US$4.4bn of iPhones to the US from India, compared with US$3.7bn in the whole of last year Nearly all the iPhones exported by Foxconn Technology Group (富士康科技集團) from India went to the US between March and last month, customs data showed, far above last year’s average of 50 percent and a clear sign of Apple Inc’s efforts to bypass high US tariffs imposed on China. The numbers, being reported by Reuters for the first time, show that Apple has realigned its India exports to almost exclusively serve the US market, when previously the devices were more widely distributed to nations including the Netherlands and the Czech Republic. During March to last month, Foxconn, known as Hon Hai Precision Industry
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) and the University of Tokyo (UTokyo) yesterday announced the launch of the TSMC-UTokyo Lab to promote advanced semiconductor research, education and talent development. The lab is TSMC’s first laboratory collaboration with a university outside Taiwan, the company said in a statement. The lab would leverage “the extensive knowledge, experience, and creativity” of both institutions, the company said. It is located in the Asano Section of UTokyo’s Hongo, Tokyo, campus and would be managed by UTokyo faculty, guided by directors from UTokyo and TSMC, the company said. TSMC began working with UTokyo in 2019, resulting in 21 research projects,
Quanta Computer Inc (廣達) chairman Barry Lam (林百里) yesterday expressed a downbeat view about the prospects of humanoid robots, given high manufacturing costs and a lack of target customers. Despite rising demand and high expectations for humanoid robots, high research-and-development costs and uncertain profitability remain major concerns, Lam told reporters following the company’s annual shareholders’ meeting in Taoyuan. “Since it seems a bit unworthy to use such high-cost robots to do household chores, I believe robots designed for specific purposes would be more valuable and present a better business opportunity,” Lam said Instead of investing in humanoid robots, Quanta has opted to invest
EXPANSION: While Gigabyte Technology is optimistic about market demand this year, uncertainty remains due to the impact of potential US tariffs and currency fluctuations Motherboard and graphics card maker Gigabyte Technology Co (技嘉) yesterday said that it plans to launch an artificial intelligence (AI) server assembly line in the US in the second half of this year. The company’s core motherboard and graphics card businesses in the US remain stable, but sales of its higher-priced AI servers still hinge on the development of tariff policies, Gigabyte chairman Dandy Yeh (葉培城) told reporters following the company’s annual shareholders’ meeting in Taipei. Yeh was referring to the “reciprocal” tariffs announced by US President Donald Trump on April 2, which were later postponed for 90 days. While Gigabyte
RSS